Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $50.00 | Buy | TD Cowen |
| 8/2/2023 | $16.00 → $12.00 | Sell → Neutral | Goldman |
| 6/26/2023 | $55.00 → $40.00 | Buy | Jefferies |
| 5/20/2022 | $5.00 | Underperform | BofA Securities |
| 2/23/2022 | $49.00 → $35.00 | Buy | B. Riley Securities |
| 1/28/2022 | $70.00 → $68.00 | Buy | HC Wainwright & Co. |
| 1/24/2022 | $75.00 → $70.00 | Buy | HC Wainwright & Co. |
| 12/1/2021 | $55.00 → $36.00 | Outperform | Evercore ISI Group |
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com
Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 Establishes $250 million credit facility to repay existing debt and to buy back up to $100 million of common stock under a share repurchase program Initiated phase 1 study in RMS patients for subcutaneous ublituximab and received FDA IND clearance to study azer-cel (allogeneic CD19 CAR-T) in patients with progressive MS Conference call to be held today, August 6, 2024, at 8:30 AM ET NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therape
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)
10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)
TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00
Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously
Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The Company's growth between fiscal years 2020 to 2023 was fueled by BRIUMVI® revenues, which was approved to treat adult individuals with relapsing forms of multiple sclerosis in December of 2022. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "We are proud to be recognized as the fastest-growing c
HOLLY SPRINGS, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies (the Company), a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today announced that TG Therapeutics, Inc. (NASDAQ:TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS). Under the terms of the manufacturing supply agreement, FUJIFILM Diosynth Biotechnologies will provide secondary US-based manufacturing supply for BRIUMVI at the Company's new biopharmaceutical manufacturing facility
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to
TG Therapeutics (NASDAQ:TGTX) has outperformed the market over the past 5 years by 9.05% on an annualized basis producing an average annual return of 22.44%. Currently, TG Therapeutics has a market capitalization of $3.35 billion. Buying $1000 In TGTX: If an investor had bought $1000 of TGTX stock 5 years ago, it would be worth $2,733.92 today based on a price of $21.68 for TGTX at the time of writing. TG Therapeutics's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated co
TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 9.38% since its last report. The company recently reported that it has 34.30 million shares sold short, which is 24.54% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.32 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inte
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:
Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity